KNC LaboratoriesKNC Laboratories Co., Ltd.6568東証グロースサービス業FY ending Mar 2026, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥11 is left as operating profit. Revenue changed +11.2% from the prior year, operating profit +32.7%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 8.6% | 0.53× | 4.6% | 1.33× | 6.2% |
| 2023 | 17.9% | 0.59× | 10.5% | 1.33× | 14.0% |
| 2024 | 16.3% | 0.54× | 8.8% | 1.39× | 12.2% |
| 2025 | 9.0% | 0.42× | 3.8% | 1.47× | 5.6% |
| 2026 | 8.4% | 0.44× | 3.7% | 1.53× | 5.6% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 7,441 | 8,628 | 9,155 | 8,179 | 9,094 |
| Cost of revenue | 5,333 | 5,324 | 5,859 | 5,858 | 6,705 |
| Gross profit | 2,107 | 3,304 | 3,296 | 2,321 | 2,388 |
| SG&A | 1,013 | 1,140 | 1,214 | 1,549 | 1,364 |
| Operating income | 1,095 | 2,164 | 2,081 | 772 | 1,025 |
| Pretax income | 917 | 2,172 | 2,093 | 928 | 1,026 |
| Income tax | 273 | 630 | 600 | 191 | 260 |
| Net income attributable to owners | 643 | 1,543 | 1,493 | 737 | 766 |
| Operating margin | 14.7% | 25.1% | 22.7% | 9.4% | 11.3% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥1.97B | ¥2.3B | ¥3.31B | ¥2.39B | ¥2.17B |
| Total assets | ¥14B | ¥15.4B | ¥18.6B | ¥20.2B | ¥21.6B |
| Net assets | ¥10.6B | ¥11.7B | ¥13.1B | ¥13.5B | ¥14.1B |
| Share capital | ¥2B | ¥2B | ¥2B | ¥2B | ¥2B |
| Property, plant and equipment | ¥6.91B | ¥7.2B | ¥8.47B | ¥11.1B | ¥12.3B |
| Intangible assets excluding goodwill | ¥45.7M | ¥63.5M | ¥53.4M | ¥51.6M | ¥61M |
| Investment securities | ¥238.3M | ¥221.5M | ¥344.3M | ¥232.6M | ¥333M |
| Current assets | ¥6.35B | ¥7.46B | ¥8.56B | ¥7.48B | ¥7.81B |
| Current liabilities | ¥2.05B | ¥2.73B | ¥2.97B | ¥2.27B | ¥2.73B |
| Short-term borrowings | ¥200M | ¥500M | — | — | — |
| Long-term borrowings | ¥1.04B | ¥596.7M | ¥1.31B | ¥2.27B | ¥2.49B |
| Total liabilities | ¥3.38B | ¥3.66B | ¥5.53B | ¥6.63B | ¥7.56B |
| Equity attributable to owners of parent | ¥10.5B | ¥11.6B | ¥12.9B | ¥13.4B | ¥13.9B |
| Retained earnings | ¥6.57B | ¥7.83B | ¥9.07B | ¥9.57B | ¥10.1B |
| Treasury stock | -¥51K | -¥78.3M | -¥67.6M | -¥53.8M | -¥43M |
EDINET (FSA Japan)
有価証券報告書－第42期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第41期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第40期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第39期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第38期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第37期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 48 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.